Applied Therapeutics, Inc.
APLTNASDAQHealthcare
$0.10
+$0.00(+0.00%)
Market Cap$14862969
P/E Ratio—
52W High$1.5
52W Low$0.09
Applied Therapeutics, Inc. (APLT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
APLT · earnings · updated Jun 8, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 13, 2025EPS Actual
-$0.13
Est. -$0.14 · +7.5%
Revenue
$0.00B
Est. $0.00B · +200.0%
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 13, 2025
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 4-Quarter EPS Beat Streak
APLT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.14 | -$0.13 | +7.5% | $0.00B | $0.00B | +200.0% |
| ▲ Q3 FY2025 | Aug 13, 2025 | -$0.17 | -$0.15 | +10.9% | — | $0.00B | — |
| ▲ Q2 FY2025 | May 13, 2025 | -$0.18 | -$0.15 | +17.4% | — | $0.00B | — |
| ▲ Q2 FY2025 | Apr 14, 2025 | -$0.18 | $0.32 | +272.4% | $-0.00B | $0.00B | -100.2% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.16 | -$0.48 | -200.8% | $0.00B | — | — |
| ▲ Q3 FY2024 | Aug 7, 2024 | -$0.16 | $0.02 | +112.2% | $0.00B | $0.00B | -94.2% |
| ▼ Q2 FY2024 | May 9, 2024 | -$0.16 | -$0.67 | -320.2% | $0.00B | $0.00B | -94.3% |
| ▼ Q1 FY2024 | Mar 6, 2024 | -$0.19 | -$0.45 | -139.5% | $-0.00B | — | — |
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.13
EPS Est.
-$0.14
EPS Surpr.
+7.5%
Revenue
$0.00B
Q3 FY2025
Aug 13, 2025Beat
EPS Actual
-$0.15
EPS Est.
-$0.17
EPS Surpr.
+10.9%
Revenue
—
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$0.15
EPS Est.
-$0.18
EPS Surpr.
+17.4%
Revenue
—
Q2 FY2025
Apr 14, 2025Beat
EPS Actual
$0.32
EPS Est.
-$0.18
EPS Surpr.
+272.4%
Revenue
$-0.00B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.48
EPS Est.
-$0.16
EPS Surpr.
-200.8%
Revenue
$0.00B
Q3 FY2024
Aug 7, 2024Beat
EPS Actual
$0.02
EPS Est.
-$0.16
EPS Surpr.
+112.2%
Revenue
$0.00B
Q2 FY2024
May 9, 2024Miss
EPS Actual
-$0.67
EPS Est.
-$0.16
EPS Surpr.
-320.2%
Revenue
$0.00B
Q1 FY2024
Mar 6, 2024Miss
EPS Actual
-$0.45
EPS Est.
-$0.19
EPS Surpr.
-139.5%
Revenue
$-0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q3 FY2027 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q2 FY2027 | $-0.09 | $-0.09 | $-0.09 | 1 |
| Q1 FY2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q4 FY2026 | $-0.13 | $-0.13 | $-0.13 | 1 |
| Q3 FY2026 | $-0.12 | $-0.12 | $-0.12 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q4 FY2025 | Nov 13, 2025 | +7.5% | $0.91 | $0.27 | -70.33% |
| ▲ Q3 FY2025 | Aug 13, 2025 | +10.9% | $0.44 | $0.45 | +2.61% |
| ▲ Q2 FY2025 | May 13, 2025 | +17.4% | $0.46 | $0.44 | -4.86% |
| ▲ Q2 FY2025 | Apr 14, 2025 | +272.4% | $0.37 | $0.37 | -0.70% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -200.8% | $9.65 | $9.74 | +0.93% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +112.2% | $6.10 | $6.20 | +1.64% |
| ▼ Q2 FY2024 | May 9, 2024 | -320.2% | $4.71 | $4.62 | -1.91% |
| ▼ Q1 FY2024 | Mar 6, 2024 | -139.5% | $6.17 | $6.46 | +4.70% |
Q4 FY2025-70.33%
Report Date
Nov 13, 2025
EPS Beat/Miss
+7.5%
Price Before
$0.91
Price After
$0.27
Q3 FY2025+2.61%
Report Date
Aug 13, 2025
EPS Beat/Miss
+10.9%
Price Before
$0.44
Price After
$0.45
Q2 FY2025-4.86%
Report Date
May 13, 2025
EPS Beat/Miss
+17.4%
Price Before
$0.46
Price After
$0.44
Q2 FY2025-0.70%
Report Date
Apr 14, 2025
EPS Beat/Miss
+272.4%
Price Before
$0.37
Price After
$0.37
Q4 FY2024+0.93%
Report Date
Nov 7, 2024
EPS Beat/Miss
-200.8%
Price Before
$9.65
Price After
$9.74
Q3 FY2024+1.64%
Report Date
Aug 7, 2024
EPS Beat/Miss
+112.2%
Price Before
$6.10
Price After
$6.20
Q2 FY2024-1.91%
Report Date
May 9, 2024
EPS Beat/Miss
-320.2%
Price Before
$4.71
Price After
$4.62
Q1 FY2024+4.70%
Report Date
Mar 6, 2024
EPS Beat/Miss
-139.5%
Price Before
$6.17
Price After
$6.46
Avg Beat Reaction-14.33%
Avg Miss Reaction+1.24%
Beat Rate5 / 8 quarters
Largest Move-70.33% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: APLT ends December
Applied Therapeutics, Inc. (APLT) most recently reported earnings on November 13, 2025 for Q4 FY2025, posting EPS of $-0.13 — beating the analyst consensus of $-0.14 by +7.5%. APLT has beaten EPS estimates for 4 consecutive quarters. The next APLT earnings date is expected around September 1, 2026.
Each quarter, investors track APLT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. APLT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
APLT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
APLT earnings · 5 questionsApplied Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. APLT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; APLT historically reports after market close (AMC).
APLT earnings datewhen is APLT earningsAPLT next earnings datewhen does APLT report earningsAPLT earnings calendar
▸ Source: FMP · Applied Therapeutics, Inc. SEC filings · US GAAP · Applied Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026